Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FREY is all about solutions. Too many issues/headaches. Look to FREY to solve the myriad of lithium battery questions.
FREY is a great $$$$$ opportunity.
FREYR Battery Enters Strategic Partnership with Hana Technology
5:59 am ET August 24, 2022 (BusinessWire) Print
FREYR Battery (NYSE: FREY) ("FREYR" or the "company"), a developer of clean, next-generation battery cell production capacity, has awarded a strategic alliance frame agreement to South Korea-based Hana Technology Co. Ltd ("Hana Technology"). Together, the two companies will jointly develop equipment and automation solutions for FREYR's Customer Qualification Plant ("CQP") in Mo i Rana, Norway, as well as for FREYR's planned Gigafactories.
Hana Technology develops precision automation solutions for battery facilities and other industrial operations. This strategic alliance frame agreement will enable FREYR and Hana Technology to customize and co-develop solutions for the CQP, including joint development projects such as quality control equipment, aging time reductions, and artificial intelligence updates to systems to reduce waste.
"We selected Hana Technology due to their proven track record with major Korean battery manufacturers. We also experienced, as part of our tender process, that they have the best technical solution to meet our needs for clean battery cell production. We aim to collaborate and co-create with them, ensuring that we move with speed and scale quickly, and make strides towards our goal to become one of the most sustainable battery producers in the world," says Tom Einar Jensen, CEO for FREYR.
Hana Technology is a pre-qualified vendor of 24M Technologies, Inc. ("24M"), the maker of the 24M SemiSolid(TM) production platform which enables lower-cost and more sustainable lithium-ion battery production. FREYR has licensed the 24M platform with the ambition to reduce the steps in the battery cell manufacturing process and subsequently reduce carbon emissions.
"FREYR's ambition to build sustainable and efficient battery production facilities is well aligned with our areas of expertise. By joining forces and co-creating technical solutions for their planned Gigafactories and for the FREYR CQP that is now underway, we aim to elevate the standards for clean, cost-efficient battery cell technology, moving fast together to meet the growing, global battery demand," says Insik Lee, Managing Director, Hana Technology.
As part of the strategic alliance frame agreement, Hana Technology will specifically support on areas including pouch assembly, formation and aging, inspection, grading, packaging, as well as scrap-discharge equipment for FREYR's Gigafactories. Hana Technology will also collaborate with FREYR to review, develop, and improve its technical documentation.
"Our bold ambitions require experienced partners, such as Hana Technology. We have secured three years of their expertise and capabilities through this agreement, with the option to extend if needed. This is yet another step towards securing the capacity we need as we head towards initial production - according to our timeline," adds Jensen.
About FREYR Battery
FREYR Battery aims to provide industrial scale clean battery solutions to reduce global emissions. Listed on the New York Stock Exchange, FREYR's mission is to produce green battery cells to accelerate the decarbonization of energy and transportation systems globally. FREYR has commenced building the first of its planned factories in Mo i Rana, Norway and announced potential development of industrial scale battery cell production in Vaasa, Finland and the United States. FREYR intends to install 50 GWh of battery cell capacity by 2025 and 100 GWh annual capacity by 2028 and 200 GWh of annual capacity by 2030. To learn more about FREYR, please visit www.freyrbattery.com
About Hana Technology
Hana Technology is one of the innovative companies for battery automation production equipment over 20 years in Korea.
Based on expertise of battery assembly equipment technology, we have broadened it to formation equipment as well. Hana Technology is focusing on expand capacity and core technology which make sure our client's production efficiency and quality battery production.
Hana Technology prioritize unique design solution, securing delivery and special maintenance so that our partner could ensure production schedule. Qualified reference in market with top tier battery manufacturer in the world could lead Hana Technology to next level in the state-of-the-art technology.
Cautionary Statement Concerning Forward-Looking Statements
All statements, other than statements of present or historical fact included in this press release, including, without limitation, statements regarding the two companies' ability to jointly develop equipment and automation solutions for FREYR's CQP and planned Gigafactories; Hana Technology's ability to meet FREYR's needs for clean battery production; FREYR's ambition to become one of the most sustainable battery producers in the world; and the 24M platform's ability to reduce the steps in the battery cell manufacturing process and reduce carbon emissions are forward-looking and involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Most of these factors are outside FREYR's control and difficult to predict. Information about factors that could materially affect FREYR is set forth under the "Risk Factors" section in (i) FREYR's Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") on August 9, 2021, as amended, and (ii) FREYR's annual report on Form 10-K filed with the SEC on March 9, 2022, and available on the SEC's website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005352/en/
SOURCE: FREYR Battery
Investor contact:
Jeffrey Spittel
Vice President, Investor Relations
jeffrey.spittel@freyrbattery.com
Tel: (+1) 281-222-0161
Media contact:
Katrin Berntsen
Vice President, Communication and Public Affairs
katrin.berntsen@freyrbattery.com
Tel: (+47) 920 54 570
comtex tracking
COMTEX_412943142/1006/2022-08-24T05:59:00
Good interview!
FIGS moving up in premarket. Ron Barron on CNBC , accumulating shares!!!!!
I like the PT's > 15.00+
Super low float > huge accumulation in process!
NERV > gangbusters!!!!!
NERV & AYLA > ratcheting upwards!
LET'S SEE 10.00+ TODAY!!!!!
Pension plans, endowment funds, & mutual funds buying this week.
You can bet scores of Cohen's clients loading NERV.
NERV > getting hysterical, jumpy, & excitable!!!!! LET'S GO NERV!
Technical & fundamental catalysts > $$$$$ > NERV
Point72 Asset Management reported an 8.8% passive stake in Minerva.
Point72 is a global asset management firm led by Steven A. Cohen that invests in multiple asset classes and strategies worldwide. We are constantly pursuing innovation in our investing processes to deliver on our mission of producing superior risk-adjusted returns.
Keeps ratcheting upwards!
AYLA up 24% @ 1.67
Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report) today and set a price target of $12.00. The company's shares closed last Tuesday at $1.69, close to its 52-week low of $0.70. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 8.9% and a 33.6% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and PDS Biotechnology. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ayala Pharmaceuticals with a $15.00 average price target.
https://www.tipranks.com/news/blurbs/noble-financial-thinks-ayala-pharmaceuticals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
8:00 am ET August 24, 2022 (Globe Newswire) Print
EQNX::TICKER_START (NasdaqGM:AYLA), EQNX::TICKER_END Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that data on the efficacy and tolerability of investigational new drug AL102 from Part A of the Phase 2/3 RINGSIDE study will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress, to take place September 8-13, 2022 in Paris, France.
The presentation details follow:
Abstract Title: Initial Results of Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors (DT)
Presentation Number: 1488MO
Session Type: Mini Oral Session
Session Title: Sarcoma
Session Date and Time: Monday, September 12, 2022, at 2:45 pm CEST / 8:45 am EDT
About the RINGSIDE study
The RINGSIDE pivotal Phase 2/3 study is a randomized multi-center trial. Part A of the study is evaluating the efficacy, safety, tolerability, and tumor volume by MRI after 16 weeks of AL102 in adult patients with desmoid tumors. It enrolled 42 patients and is evaluating 3 doses of AL102. Patients who participated in Part A will be eligible to enroll into an open-label extension study at the selected Part B dose, and long-term efficacy and safety will be monitored. Part B of the study will be double-blind, placebo-controlled, and will start immediately after dose selection from part A, enrolling up to 156 adult and adolescent patients with progressive disease, randomized between AL102 or placebo. The study's primary endpoint is progression-free survival (PFS) with secondary endpoints including objective response rate (ORR), duration of response (DOR), and patient-reported Quality of Life (QOL) measures.
For more information on the RINGSIDE Phase 2/3 study with AL102 for the treatment of desmoid tumors, please visit ClinicalTrials.gov and reference Identifier NCT04871282 (RINGSIDE).
About Desmoid Tumors
Desmoid tumors also called aggressive fibromatosis or desmoid-type fibromatosis, are rare connective tissue tumors that typically arise in the upper and lower extremities, abdominal wall, head and neck area, mesenteric root, and chest wall with the potential to arise in additional parts of the body. Desmoid tumors do not metastasize, but often aggressively infiltrate neurovascular structures and vital organs. People living with desmoid tumors are often limited in their daily life due to chronic pain, functional deficits, general decrease in their quality of life and organ dysfunction. Desmoid tumors have an annual incidence of approximately 1,700 patients in the United States and typically occur in patients between the ages of 15 and 60 years. They are most commonly diagnosed in young adults between 30-40 years of age and are more prevalent in females. Today, surgery is no longer regarded as the cornerstone treatment of desmoid tumors due to high rate of recurrence post-surgery and there are currently no FDA-approved systemic therapies for the treatment of unresectable, recurrent or progressive desmoid tumors.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE). For more information, visit www.ayalapharma.com.
Contacts
Investors:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The Company's portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors (GSIs). AL101 and AL102 are designed to address the underlying key drivers of tumor growth. The Company is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma (R/M ACC), for patients bearing Notch-activating mutations. The Company also developing AL102 for the treatment of other rare indications including T-ALL, an aggressive, rare form of T-cell specific leukemia. The Company is also conducting its ongoing Phase II ACCURACY trial for the treatment of R/M ACC in subjects with progressive disease and Notch-activating mutations.
Agree! Nice corporate website, and GIF, + $olid AH. > LET'S GO STBX !
18.99
STBX
18.03
STBX
16.25 > ratcheting back up in AH.
STBX
My 10' s starting to look good! Maybe much higher in AH.
LOL, Soon I am going golfing with Lacey Underall. She is the pro @ Bushwood Country Club.
Congrats buddy! Hope your bike is not electric! .....lol
Watch it close @ high of the day.....lol
I got 10.24's and 10.72's
10.00's now
Halted @ 11.99
Looking to place an order now!
STBX
12.76 may be low of the day !
INDO @ 8.76 > NAT GAS > recent news > while drilling the Kruh 28 well on IEC’s Kruh block, IEC unexpectedly found evidence of a potential natural gas bearing reservoir between 976 and 1,006 feet interval with 25 feet net thickness. This initial evidence was supported by both wireline logging and geologic logging data.
INDO > 8.89 up 14%
How about those 2 hood belts! > Yo momma so fat, her belt size is E for Equator.
1938 Peugeot 402 Darl’mat Special Coupe
1 of 6 built on the 402-Series
1 of 3 surviving examples
A Unique & Magnificent piece of French automotive history
VDRM IS A GREAT $$$$$ OPPORTUNITY.
REVENUES > "much closer to having to fulfill large purchase orders" > $$$$$
VDRM